within Pharmacolibrary.Drugs.ATC.R;

model R03DX11
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 2.8333333333333335e-06,
    adminDuration  = 600,
    adminMass      = 210 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0055,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0037,
    k12             = 0.47,
    k21             = 0.47
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R03DX11</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Tezepelumab is a human monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), used for the treatment of severe asthma. It is approved for clinical use in adults and adolescents with severe, uncontrolled asthma despite standard therapy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in healthy adults and patients with severe asthma receiving subcutaneous administration.</p><h4>References</h4><ol><li><p>Sakamoto, K, et al., &amp; Ren, S (2020). A Phase 1, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Subcutaneous Tezepelumab in Healthy Japanese Men. <i>Clinical pharmacology in drug development</i> 9(7) 833–840. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.775&quot;>10.1002/cpdd.775</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31960624/&quot;>https://pubmed.ncbi.nlm.nih.gov/31960624</a></p></li><li><p>Ly, N, et al., &amp; Roskos, L (2021). Pharmacokinetic and Pharmacodynamic Modeling of Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe Asthma. <i>Journal of clinical pharmacology</i> 61(7) 901–912. DOI:<a href=&quot;https://doi.org/10.1002/jcph.1803&quot;>10.1002/jcph.1803</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33368307/&quot;>https://pubmed.ncbi.nlm.nih.gov/33368307</a></p></li><li><p>Zheng, Y, et al., &amp; Colice, G (2021). Tezepelumab Pharmacokinetics, Safety, and Tolerability After Administration via Vial-and-syringe, Accessorized Prefilled Syringe, or Autoinjector: A Randomized Trial in Healthy Volunteers. <i>Clinical therapeutics</i> 43(1) 142–155.e5. DOI:<a href=&quot;https://doi.org/10.1016/j.clinthera.2020.11.014&quot;>10.1016/j.clinthera.2020.11.014</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33380362/&quot;>https://pubmed.ncbi.nlm.nih.gov/33380362</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R03DX11;
